Elderly patients with acute myeloid leukemia: Characteristics in biology, patients, and treatment;Alte patienten mit akuter myeloischer leukämie - Charakteristika der biologie, des patienten und der therapie

Medizinische Klinik

Volumn 98, Issue 4, 2003, Pages 193-207

  Wedding, Ulrich ^a,d   Bokemeyer, Carsten ^b   Meran, Johannes Gobertus ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c WILHELMINEN HOSPITAL   (Austria)

^d Klinik fur Innere Medizin I   (Germany)

Author keywords

Age; AML; Chemotherapy; Comorbidity; Palliative

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; THALIDOMIDE; TIOGUANINE; TIPIFARNIB; TOPOTECAN; VALSPODAR; VINCRISTINE; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; AGED; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; ELDERLY CARE; FOLLOW UP; HUMAN; INFECTION; NEUTROPENIA; REVIEW; SIDE EFFECT; TOXICITY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; GROWTH SUBSTANCES; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 0037447208     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1244-2     Document Type: Review

References (78)

1. Rule S, Poirer V, Singer C. Management of acute myeloid leukaemia. A regional audit in the south and west of the United Kingdom. Clin Med 2001;1:313-6.
2. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-76.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
4. Head DR. Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful? Curr Opin Oncol 2002;14:19-23.
5. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
6. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98: 1312-20.
7. Rossi G, Pelizzari AM, Bellotti D, Tonelli M, Barlati S. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia 2000;14:636-41.
8. Leith CP, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 1999;94:1086-99.
9. Löwenberg B. Managing therapy in older adult patients with acute myeloid leukemia. Semin Hematol 2001;38:10-6.
10. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
11. Garrido SM, Cooper JJ, Appelbaum FR, Willman CL, Kopecky K, Blanker DE. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res 2001;25:23-32.
12. Sheikhha MH, Tobal K, Liu Yin JA. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002;117:359-65.
13. Matthews JP, Bishop JF, Young GA, Juneja SK, Lowenthal RM, Garson OM, Cobcroft RG, Dodds AJ, Enno A, Gillett EA, Hermann RP, Joshua DE, Ma DD, Szer J, Taylor KM, Wolf M, Bradstock KF. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br J Haematol 2001;113:727-36.
14. Estey EH. How I treat older patients with AML. Blood 2000;96:1670-3.
15. Spataro V, Kovacsovics T, Bach S, Pampallona S, Schapira M, Cavalli F. Acute myeloid leukemia in the elderly: results of an individualized approach in two centres. Leuk Lymphoma 2000;39:521-30.
16. Pinquart M, Silbereisen. Entscheidungsprozesse der Krebspatienten. Zusammenhänge mit dem Alter und der Lebensqualität. Onkologe 2002;8:161-6.
17. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kanrajian HM, Beran M. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001; 98:3575-83.
18. Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002;14:24-30.
19. Goldstone AH, Bornett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-11.
20. DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996;93:89-95.
21. Anonymous. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998;103:100-9.
22. Glasmacher A, Gorschlüter M, Hahn C, Mey U, Schmidt-Wolfl. Idarubicin versus daunorubicin for induction therapy of acute myeloid leukemia: a metaanalysis of 1341 patients in 6 randomized trials. Blood 2001;98:2478.
23. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16:872-81.
24. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896-903.
25. Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R. Use of recombinant GM-CSF duringand after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Group. Blood 1997;90:2952-61.
26. Stein RS, Vogler WR, Winton EF, Cohen HJ, Raney MR, Bartolucci A. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. Leuk Res 1990;14:895-903.
27. Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Hoffken K, Bergmann L, Hoelzer D. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). Ann Hematol 2000;79:30-5.
28. Buechner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Löffler H, Haferlach T, Staib P, Grüneisen A, Aul C, Heyll A, Lengfelder E, Ludwig WD, Maschmeyer G, Rasche H, Eimermacher H, Balleisen L, Pielken HJ, Reis HE, Griesinger F, Reichle A, Schott G, Sauerland MC, Heinecke A. Requestioning the role of prolonged maintenance chemotherapy in AML: randomized trial by the German AML Cooperative Group updated. Blood 2001;98:1933.
29. Giles FJ. Novel agents for the therapy of acute leukemia. Curr Opin Oncol 2002;14:3-9.
30. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-84.
31. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6.
32. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001;13:522-7.
33. Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001;113:713-26.
34. Steins MB, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, Kessler T, Buechner T, Berdel WE, Mesters RM. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002;99:834-9.
35. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood 2001;97:3361-9.
36. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001;97:1413-21.
37. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A, Catalano G, Del Moro B, Cudillo L, Postorino M, Masi M, Amadori S. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948-52.
38. Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, Oliva E, Schiavone EM, Pollio F, Palmieri S, Gianfaldoni G, Leoni F. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. Haematologica 2001;86:814-20.
39. Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann R, Buchner T, Hiddemann W. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 1998;12:1049-55.
40. Kusnierz-Glaz CR, Normann D, Weinberg R, Fuchs S, Flasshove M, Hiddemann W, van de Loo J, Buchner T. Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia. Hematol Oncol 1993;11:73-80.
41. Sayer HG. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003:in press.
42. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, Desablens B, Henry-Amar M, Degos L. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272-9.
43. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-74.
44. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986;4:1857-64.
45. Harousseau JL, Rigal-Huguet F, Hurteloup P, Guy H, Milpied N, Pris J. Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent. Eur J Haematol 1989;42:182-5.
46. Bouabdallah R, Lefrere F, Rose C, Chaibi P, Harousseau JL, Vernant JP, Castaigne S, Bauduer F, Zini JM, Coso D, Varet B, Robert J, Fenaux P. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients. Leukemia 1999;13:1491-6.
47. Bokemeyer C, Honecker F, Wedding U, Spath-Schwalbe E, Lipp HP, Kolb G. Use ofhematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. Onkologie 2002;25:32-9.
48. Geissler K, Kabma E, Stengg S, Schwarzinger I, Knobl P, Valent P, Eichinger S, Barge A, Lechner K. Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. Br J Haematol 1998;102:535-43.
49. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewen C, Matcham J, Hoelzer D. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEGr-HuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94:3694-701.
50. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM. A double-blind, placebocontrolled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000;95:2530-5.
51. Maschmeyer G. Therapie infektiöser Krankheiten. In: Höffken K, Kolb G, Wedding U, Hrsg. Geriatrische Onkologie. Heidelberg: Springer, 2002:346-57.
52. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA; Clegg L, Edwards BKE. SEER cancer statistics review, 1973-1998. Bethesda/MD: National Cancer Institute, 2001 (http://seer.cancer.gov/Publications/CSR1983-1988/).
53. Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996;94:89-98.
54. Biichner T, Hiddemann W, Wörmann B. Daunorubicin 60 instead of 30mg/sqm improves response and survival in elderly patients with AML. Blood 1997;90:583a.
55. Yates J, et Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60:454-62.
56. Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH. Full dose versus attenuated dose daunombicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984;2:865-70.
57. Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Faberes C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996;10:389-95.
58. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O'Connell MJ. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988;6;583-7.
59. Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Weiler C, Glick JH. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984;63:843-7.
60. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79:1924-30.
61. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR, Bloomfield CD, Schiffer CA. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98:548-53.
62. Yoshida S, Kuriyama K, Miyazaki Y, Taguchi J, Fukushima T, Honda M, Hayashibara T, Nagai K, Atogami S, Toriya K, Soda H, Nonaka H, Momita S, Jinnai I, Amenomori T, Kusano M, Yoshida Y, Ikeda S, Matsuo T, Tomonaga M. De novo acute myeloid leukemia in the elderly; a consistent fraction of longterm survivors by standard-dose chemotherapy. Leuk Res 2001;25:33-8.
63. Sebban C, Archimbaud E, Coiffier B, Guyotat D, Treille-Ritouet D, Maupas J, Fiere D. Treatment of acute myeloid leukemia in elderly patients. A retrospective study. Cancer 1988;61:227-31.
64. Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001;115:25-33.
65. Bassan R, Buelli M, Viero P, Minotti C, Barbui T. The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. Hematol Oncol 1992;10:251-60.
66. Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M. De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital. Leuk Lymphoma 1999;35:289-96.
67. Orlandi E, et Lazzarino M, Morra E, Castagnola C, Alessandrino EP, Bernasconi P, Bonfichi M, Bernasconi C. Impact of advanced age on the management of acute nonlymphocytic leukemia: a study of 103 patients. Acta Haematol 1990;84:144-8.
68. Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma 1998;29:375-82.
69. Taylor PR, Reid MM, Stark AN, Bown N, Hamilton PJ, Proctor SJ. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia 1995;9:231-7.
70. Lopez A, de la Rubia J, Martin G, Martinez J, Cervera J, Jarque I, Sempere A, Plume G, Saavedra S, Regadera A, Sanz G, Gomis F, Perez-Sirvent ML, Senent J, Jimenez C, Sanz MA. Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leuk Res 2001; 25:685-92.
71. Baudard M, Beauchamp-Nicoud A, Delmer A, Rio B, Blanc C, Zittoun R, Marie JP. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 1999;13:1481-90.
72. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH. A randomized placebo-controlled phase III study of granulocyte-macrophage colonystimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62.
73. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995;332:1678-83.
74. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995;332:1671-7.
75. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cabn JY, Lioure B, Witz B, Francois S, Desablens B, Pignon B, Le Prise PY, Audhuy B, Caillot D, Casassus P, Delain M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau JL. A placebo-controlled study of recombinant human granulocytemacrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998;91: 2722-30.
76. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90:4710-8.
77. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998;91:3607-15.
78. Rowe JM. Concurrent use of growth factors and chemotherapy in acute leukemia. Curr Opin Hematol 2000;7:197-202.